BLRX Latest Press Releases

-- October 23, 2026 --

BioLineRx and Hemispherian Present Preclinical Data Demonstrating Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancer at ESMO 2026 PRNewswire 7:01 AM

-- October 8, 2026 --

BioLineRx and Hemispherian Announce Two GLIX1 Presentations at the 31st Society for Neuro-Oncology (SNO) Annual Meeting & Education Day PRNewswire 7:01 AM

-- September 10, 2026 --

BioLineRx and Hemispherian AS to Present Encouraging GLIX1 Preclinical Efficacy Data and its Phase 1/2a Trial Design at the 21st Meeting of the European Association of Neuro-Oncology (EANO 2026) PRNewswire 7:00 AM

-- August 31, 2026 --

BioLineRx Reports Second Quarter 2026 Financial Results and Provides Corporate Update PRNewswire 7:00 AM

-- August 28, 2026 --

BioLineRx Announces $3.75 Million Registered Direct Offering and Concurrent Private Placement PRNewswire 8:00 AM

-- August 25, 2026 --

BioLineRx to Report Second Quarter 2026 Results on August 31, 2026 PRNewswire 7:00 AM

-- July 20, 2026 --

BioLineRx and Hemispherian AS to Present Data Demonstrating Strong Synergy of GLIX1 with PARP Inhibitors in HR-Proficient Ovarian Cancers at ESMO 2026 PRNewswire 7:00 AM

-- July 8, 2026 --

BioLineRx and Hemispherian Announce New Preclinical Data Demonstrating Strong Synergistic Effect between GLIX1 and PARP Inhibitor in a Patient-Derived Ovarian Cancer Xenograft Model PRNewswire 7:00 AM

Market Data Delayed 15 Minutes